Clinical management of localized undifferentiated sinonasal carcinoma: our experience and review of the literature

Francesco Perri, Giuseppina Della Vittoria Scarpati, Franco Ionna, Francesco Longo, Massimo Montano, Paolo Muto, Vincenzo Ravo, Mario Giuliano, Francesco Caponigro

Research output: Contribution to journalArticle

Abstract

Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.

Original languageEnglish
Pages (from-to)308-312
Number of pages5
JournalAnti-Cancer Drugs
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Therapeutics
Neoplasms
Radiotherapy
Olfactory Esthesioneuroblastoma
Neuroendocrine Carcinoma
Inborn Genetic Diseases
Sinonasal undifferentiated carcinoma
Melanoma
Lymphoma
Clinical Trials
Drug Therapy
Survival
Nasopharyngeal carcinoma

Cite this

Clinical management of localized undifferentiated sinonasal carcinoma : our experience and review of the literature. / Perri, Francesco; Della Vittoria Scarpati, Giuseppina; Ionna, Franco; Longo, Francesco; Montano, Massimo; Muto, Paolo; Ravo, Vincenzo; Giuliano, Mario; Caponigro, Francesco.

In: Anti-Cancer Drugs, Vol. 30, No. 3, 03.2019, p. 308-312.

Research output: Contribution to journalArticle

@article{215628a5d13f49958abd1a0048bed492,
title = "Clinical management of localized undifferentiated sinonasal carcinoma: our experience and review of the literature",
abstract = "Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.",
author = "Francesco Perri and {Della Vittoria Scarpati}, Giuseppina and Franco Ionna and Francesco Longo and Massimo Montano and Paolo Muto and Vincenzo Ravo and Mario Giuliano and Francesco Caponigro",
year = "2019",
month = "3",
doi = "10.1097/CAD.0000000000000707",
language = "English",
volume = "30",
pages = "308--312",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical management of localized undifferentiated sinonasal carcinoma

T2 - our experience and review of the literature

AU - Perri, Francesco

AU - Della Vittoria Scarpati, Giuseppina

AU - Ionna, Franco

AU - Longo, Francesco

AU - Montano, Massimo

AU - Muto, Paolo

AU - Ravo, Vincenzo

AU - Giuliano, Mario

AU - Caponigro, Francesco

PY - 2019/3

Y1 - 2019/3

N2 - Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.

AB - Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.

U2 - 10.1097/CAD.0000000000000707

DO - 10.1097/CAD.0000000000000707

M3 - Article

C2 - 30779722

VL - 30

SP - 308

EP - 312

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -